The study is scheduled to start this month.
News & Analysis: Inovio Pharmaceuticals
As companies race to produce a coronavirus vaccine, half of Americans may not be interested, and that haste may be part of the reason.
Comments from Dr. Anthony Fauci and a decision by the White House weighed on the stock.
Dozens of drugmakers are developing COVID-19 vaccines and gearing up to produce billions of doses each year.
Inovio’s coronavirus vaccine trials and positive preclinical data lifted the shares.
The coronavirus vaccine race offers these clinical stage companies an opportunity to bring a first product to market -- if all goes well in human trials.
Inovio is a step behind Moderna on the coronavirus vaccine timeline -- but study results will determine the true winner.
The company is racing through the early stage of the development of its potential vaccine for COVID-19.
INO earnings call for the period ending March 31, 2020.
Size may matter in the long run.